Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated ...
Astellas Pharma is spreading its bets in neurodegenerative disorders, committing $50 million to AviadoBio for the opportunity to license its lead program, an experimental gene therapy for a type of ...
Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, along with scientists from the Broad Institute of MIT and Harvard, will present ...
The FDA has approved Otarmeni, the first gene therapy for genetic hearing loss, through its National Priority Voucher program. The therapy is indicated for pediatric and adult patients with ...
- Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential new ...
The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both ...
Forms a Wholly-Owned Subsidiary, Convergen Biotech, Inc., to Focus Diabetes Program Development The licensed technologies are based on the same general gene therapy approach under Genprex's original ...
With gene editing widely touted as the future of agricultural biotechnology, seed trait developers are looking for ways to show they are using the technology responsibly. The latest move is the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min University of Pennsylvania cites ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results